Journal
CANCER CELL
Volume 26, Issue 5, Pages 605-622Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2014.10.006
Keywords
-
Categories
Funding
- Enlight
- Ophthotech
- SynDevRx
- NIH [P01CA080124, R01CA163815]
- Proton Beam/Federal Share Program
- Department of Defense Breast Cancer Innovator Award
- National Foundation for Cancer Research
Ask authors/readers for more resources
Ten antiangiogenic drugs targeting VEGF or its receptors are approved for cancer treatment. However, these agents, intended to block tumors' blood supply, may cause hypoxia, which may fuel tumor progression and treatment resistance. Emerging clinical data suggest that patients whose tumor perfusion or oxygenation increases in response to these agents may actually survive longer. Hence, strategies aimed at alleviating tumor hypoxia while improving perfusion may enhance the outcome of radiotherapy, chemotherapy, and immunotherapy. Here I summarize lessons learned from preclinical and clinical studies over the past decade and propose strategies for improving antiangiogenic therapy outcomes for malignant and nonmalignant diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available